Journal
NEOPLASIA
Volume 12, Issue 7, Pages 590-U95Publisher
ELSEVIER SCIENCE INC
DOI: 10.1593/neo.10726
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) [CA125612]
- Early Detection Research Network [U01CA111275-06]
- Prostate Cancer Foundation [P50CA69568, R01CA132874]
- Doris Duke Charitable Foundation
- Burroughs Welcome Foundation
- Dana-Farber Harvard Cancer Center
Ask authors/readers for more resources
TMPRSS2-ERG gene fusions occur in 50% of prostate cancers and result in the overexpression of a chimeric fusion transcript that encodes a truncated ERG product. Previous attempts to detect truncated ERG products have been hindered by a lack of specific antibodies. Here, we characterize a rabbit anti-ERG monoclonal antibody (clone EPR 3864; Epitomics, Burlingame, CA) using immunoblot analysis on prostate cancer cell lines, synthetic TMPRSS2-ERG constructs, chromatin immunoprecipitation, and immunofluorescence. We correlated ERG protein expression with the presence of ERG gene rearrangements in prostate cancer tissues using a combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analysis. We independently evaluated two patient cohorts and observed
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available